Page 150 - Read Online

Page 12 of 15 Zacharakis et al. Hepatoma Res 2018;4:65 I http://dx.doi.org/10.20517/2394-5079.2018.76

22. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver
disease. N Engl J Med 1993;328:1797-1801.
23. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with
chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
24. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis
C: results from the HALT-C trial. J Hepatol 2005;43:434-41.
25. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020-2.
26. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in
hepatocellular carcinoma. Cancer Res 2007;67:10831-9.
27. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis,
and therapy. Annu Rev Med 2010;61:317-28.
28. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. Integrative transcriptome analysis reveals common molecular subclasses
of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
29. Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular
carcinoma. Am Surg 2010;76:1210-3.
30. Rimola J, Forner A, Reig M, Vilana R, de Lope CR, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases
by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009;50:791-8.
31. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical
practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
32. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
33. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with
cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
34. Li C, Shen JY, Zhang XY, Peng W, Wen TF, et al. Predictors of futile liver resection for patients with Barcelona clinic liver cancer stage B/C
hepatocellular carcinoma. J Gastrointest Surg 2018;22:496-502.
35. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, et al. Metroticket 2.0 model for analysis of competing risks of death after liver
transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128-39.
36. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma
detected during surveillance. Gastroenterology 2004;126:1005-14.
37. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic
patients is associated with development of hepatocellular carcinoma. Int J cancer 2006;119:735-40.
38. Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, et al. Staging systems for hepatocellular carcinoma: current status and future
perspectives. World J Hepatol 2015;7:406-24.
39. Liu L, Zhao Y, Jia J, Chen H, Bai W, et al. The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma
treated with sorafenib combined with transarterial chemoembolization. Sci Rep 2016; doi: 10.1038/srep19851.
40. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, et al. Usefulness of alpha-fetoprotein response in patients treated with
sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012;57:101-7.
41. Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, et al. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes
in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2013;25:683-9.
42. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J
Gastroenterol 2015;21:10573-83.
43. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma
from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-21.
44. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay
predicts early detection of hepatocellular carcinoma. J Gastroenterol 2014;49:555-63.
45. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development
of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-9.
46. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, et al. Clinical utility of AFP-L3% measurement in North American patients with
HCV-related cirrhosis. Am J Gastroenterol 2007;102:2196-205.
47. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, et al. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and
treatment of hepatocellular carcinoma. J Transl Med 2007;5:3.
48. Zhang D, Liu Z, Yin X, Qi X, Lu B, et al. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: a
systematic review and meta-analysis. Int J Biol Markers 2018;33:266-74.
49. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D,
Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in
early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
50. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for
the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502.
51. Liu Z, Ma Y, Yang J, Qin H. Upregulated and downregulated proteins in hepatocellular carcinoma: a systematic review of proteomic
profiling studies. OMICS 2011;15:61-71.
52. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers
associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013;144:1066-75.